According to official website data of Shanghai Taibo Group, Shanghai Taibo Group plans to be listed on the Science and Technology Innovation Board in May 2024.
After listing, Shanghai Taibo Group will greatly reduce Kelun's debt ratio, investment and research fees and financial expenses, and increase the profits of generic drugs.